Search

everythinglearnresearchcommunity

for

Search:↓

Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

Upadacitinib effectively treats pyoderma gangrenosum.

The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.

PX-12 may help treat psoriasis by blocking inflammation and cell death.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

The document did not conclude on apremilast's effectiveness for severe alopecia areata.

Upadacitinib improved multiple immune-related conditions in one patient.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.

Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.

Dupilumab significantly improved a 5-year-old girl's prurigo nodularis without side effects.

EGFR inhibitors can cause yellowish skin eruptions.

Teprotumumab for thyroid eye disease commonly causes fatigue, brittle nails, dry eyes, hair loss, muscle spasms, and dry mouth, with rare serious events like blood clots.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

Cetuximab can cause eyelash growth, which is rare but manageable.

Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.

An 82-year-old man's white hair regained color after taking etretinate for psoriasis.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

A man with Acrodermatitis continua did not get better with etanercept treatment, and his condition worsened, suggesting treatment effectiveness may vary by genetics and race.

Upadacitinib may effectively treat resistant lichen planopilaris.

Significant progress was made in understanding PXE, but effective treatments are still needed.

The new model helps understand and develop treatments for genetic skin disorders like AEC.

BKN-1 antibody targets specific keratin in basal cell epithelioma and normal skin basal cells.

BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.

Certain peptides can prevent hair loss in young rats caused by a cancer drug.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.